title: Peripheral blood lymphocyte number and phenotype prior to therapy correlate with response in subcutaneously applied rIL-2 therapy of renal cell carcinoma.
abstract: The phenotype of peripheral blood lymphocytes of 27 renal cell carcinoma patients before and at the end of subcutaneously given rIL-2 therapy was determined by two colour flow cytometry. Therapy induced changes in peripheral blood leucocyte composition and phenotypes were comparable to those reported for intravenously given rIL-2. The present paper shows a correlation between the 'activation status' of the patient before therapy and eventual response.
authors.affiliation: Department of Clinical Immunology, University Hospital Groningen, The Netherlands.
authors.forename: R A
authors.initials: RA
authors.lastname: Janssen
authors.forename: D T
authors.initials: DT
authors.lastname: Sleijfer
authors.forename: A A
authors.initials: AA
authors.lastname: Heijn
authors.forename: N H
authors.initials: NH
authors.lastname: Mulder
authors.forename: T H
authors.initials: TH
authors.lastname: The
authors.forename: L
authors.initials: L
authors.lastname: de Leij
mesh_terms: D000328:Adult; D000368:Aged; D002292:Carcinoma, Renal Cell / Q000097:blood* / Q000276:immunology / Q000628:therapy; D005260:Female; D006801:Humans; D007279:Injections, Subcutaneous; D007376:Interleukin-2 / Q000008:administration & dosage*; D007680:Kidney Neoplasms / Q000097:blood* / Q000276:immunology / Q000628:therapy; D007958:Leukocyte Count; D016131:Lymphocyte Subsets; D008297:Male; D008875:Middle Aged; D010641:Phenotype; D011994:Recombinant Proteins / Q000008:administration & dosage
chemical_list: D007376:Interleukin-2; D011994:Recombinant Proteins